LBA11 Individual patient data meta-analysis of 5 non-inferiority RCTs of reduced duration single agent adjuvant trastuzumab in the treatment of HER2 positive early breast cancer
Helena Earl(University of Cambridge), Xavier Pivot(Levi Strauss (United States)), V. Georgoulias(University Hospital of Heraklion), Gilles Romieu(Institut de Cancérologie de l'Ouest), Valentina Guarneri(Istituto Oncologico Veneto), PierFranco Conte(University of Padua), Julie Dunn, Andrew Wardley(UK Research and Innovation), Henrik Lindman(Uppsala University), Judith Fraser(Beatson West of Scotland Cancer Centre), M. Debled(Institut Bergonié), James Abraham(Drexel University), Céline Faure-Mercier(Institut National du Cancer), Teppo Huttunen, Heikki Joensuu(Orion Corporation (Finland)), D Cox(Centre Léon Bérard), Louise Hiller(University of Warwick), David Cameron(Corewell Health), D.W. Miles(Mount Vernon Cancer Centre), Roberto D’Amico(University of Modena and Reggio Emilia)
Cited by 25
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
|New England Journal of Medicine|2002|4.4k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes
|Nature Communications|2016|1.8k